Danaher operating subsidiary Cytiva has announced the next generation of its Biacore 8 series SPR systems, designed to generate reliable interaction data faster as drug discovery increases in complexity.
The new Biacore 8S and Biacore 8S+ systems will bring together rapid screening and high-quality molecular characterisation in a single approach, which Cytiva said will reduce hands-on time through integrated plate handling, automated workflows and extended unattended operation.
Tim Bervoets, President, Discovery & Medical, Cytiva, said: "Scientists are being asked to move faster while working with increasingly complex molecules and tighter resources."
The next generation of Biacore 8 series systems is designed to help teams focus their time and investment on the most promising candidates by delivering confident interaction data earlier in the discovery process.
The new systems will be able to screen 384 proteins in about 15 minutes, making them 16 times faster than the previous generation.
This improvement, Cytiva said, will allow scientists to broaden their screening activities and analyse complex interactions during late-stage characterisation.
The firm is also upgrading its Biacore Insight Software to version 7.0, which features Sensorgram comparison.
This function generates an objective similarity score from full interaction profiles, helping scientists evaluate comparability against reference samples.
It supports applications such as biosimilar comparability and batch-to-batch monitoring while ensuring compliance with 21 CFR Part 11.
The Biacore 8S and Biacore 8S+ systems, along with the updated software, will be available for order in summer 2026.